{"id":284059,"date":"2018-10-30T16:21:01","date_gmt":"2018-10-30T16:21:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=284059"},"modified":"2018-10-30T16:21:01","modified_gmt":"2018-10-30T16:21:01","slug":"respiratory-inhalers-market-promises-a-significant-fortune-with-approximate-cagr-during-forecast-period-20182023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/respiratory-inhalers-market-promises-a-significant-fortune-with-approximate-cagr-during-forecast-period-20182023_284059.html","title":{"rendered":"Respiratory Inhalers Market Promises a Significant Fortune with Approximate CAGR During Forecast Period 2018-2023"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Respiratory Inhalers Market”<\/div>\n<\/div>\n<\/div>\n
Market Research Future has released a new report on the Global Respiratory Inhaler Market which reveals a notable CAGR of 6.1% during the forecast period of 2017 to 2023 with an estimated value of $33,572.9 million by the end of 2023.<\/div>\n

Global Respiratory Inhalers Market – Competitive Analysis<\/strong><\/p>\n

February 2017<\/strong> – Adherium’s<\/strong> partnering and market expansion for the ‘Rest of World’ territories, including countries in Asia Pacific and the Middle East where Adherium already has sanctions to market its Smart inhaler products in China, Australia and New Zealand. This has increased the company’s strength in these countries.<\/p>\n

January 2017<\/strong> – AstraZeneca <\/strong>had announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide\/formoterol) Inhalation Aerosol. Symbicort is approved in the US to treat asthma in patients 12 years and older and for the maintenance and treatment of COPD in adults, the company is expecting larger market share with the product launch.<\/p>\n

Global Respiratory Inhaler Market – Insights<\/strong><\/p>\n

Respiratory Inhalers are medical devices that are used to assist a patient encountering breathing problems resulting from respiratory disorders such as fibrosis, asthma, COPD and ARDS and others. Market Research Future has released a new report on the Global Respiratory Inhaler Market which reveals a notable CAGR of 6.1% during the forecast period of 2017 to 2023 with an estimated value of $33,572.9 million by the end of 2023.<\/p>\n

Get Sample report @ <\/em><\/strong>https:\/\/www.marketresearchfuture.com\/sample_request\/3110<\/a><\/em><\/p>\n

There are some major drivers, driving the market growth such as rising prevalence of respiratory disorders due to increase pollution and unhealthy lifestyle, increasing usage of combination therapies due to associated benefits such as more reliable in complex patients, increased efficacy and easy reimbursement policies associated with them and others. Various restraints, which are restricting the market growth includes side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.<\/p>\n

Global Respiratory Inhaler Market – Key Players<\/strong><\/p>\n

The major participants of this market are<\/p>\n